.gif)
A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.
A team has developed a new potential antiviral drug to combat infection from SARS-CoV-2, the virus causing the COVID-19 pandemic. Named Molnupiravir (MK-4482/EIDD-2801), the molecule was originally developed by Emory University, US, and was licensed by Ridgeback Biotherapeutics for development, in collaboration with Merck.
The study was conducted at the Institute for Biomedical Sciences at Georgia State University, US. The group, led by Dr Richard Plemper, originally discovered that the drug is potent against influenza viruses and completely suppresses virus transmission within 24 hours.
Source:https://www.drugtargetreview.com/news/77877/oral-drug-blocks-sars-cov-2-transmission-in-ferrets-researchers-find/
